How Much Are Biosimilars Used in Clinical Practice A Retrospective Italian Population-Based Study of Erythropoiesis-Stimulating Agents in the Years 2009–2013Reportar como inadecuado




How Much Are Biosimilars Used in Clinical Practice A Retrospective Italian Population-Based Study of Erythropoiesis-Stimulating Agents in the Years 2009–2013 - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

BioDrugs

, Volume 29, Issue 4, pp 275–284

First Online: 14 July 2015

Abstract

PurposeTo explore the prescription patterns of erythropoiesis-stimulating agents ESAs in four large Italian geographic areas, where different health policy interventions to promote biosimilar use in routine care are undertaken.

MethodsA retrospective drug utilization study was conducted during the years 2009–2013. The data sources were the administrative databases of the Tuscany region and of the Caserta, Palermo, and Treviso Local Health Units LHUs. The characteristics, prevalence, and switching patterns of different ESAs biosimilars and reference products, stratified by indication for use, were calculated over time and across centers.

ResultsOverall, 49,491 patients were treated with ESAs during the years 2009–2013 in the four centers. Of these, 41,286 patients 83.4 % were naive users. The prevalence of ESA use increased from 2.9 to 3.4 per 1000 inhabitants in the years 2009–2011 but decreased thereafter 3.0 per 1000 in 2013. Moreover, the proportion of biosimilar users increased overall from 1.8 % in 2010 to 33.6 % in 2013, with larger increase in Treviso from 0.0 to 45.0 % and Tuscany from 0.7 to 37.6 % than in Caserta from 7.5 to 22.9 % and Palermo from 0.0 to 27.7 %. Switching between different ESAs during the first year of therapy was frequent 17.0 %, much more toward reference products than toward biosimilars.

ConclusionOverall, the prevalence of ESA use decreased slightly, while use of biosimilar ESAs, especially in naive patients, increased significantly but to different extents in these four large Italian geographic areas. Switching between different ESAs during the first year of treatment was very frequent, which may affect pharmacovigilance monitoring. New strategies are necessary to further improve market penetration of low-cost medicines, such as biosimilars, and also to harmonize effective health policy interventions that aim to reduce pharmaceutical expenses and optimize patient benefit across all regions.

Electronic supplementary materialThe online version of this article doi:10.1007-s40259-015-0132-7 contains supplementary material, which is available to authorized users.

Download fulltext PDF



Autor: Ylenia Ingrasciotta - Francesco Giorgianni - Jenny Bolcato - Alessandro Chinellato - Roberta Pirolo - Daniele Ugo Tari - Ch

Fuente: https://link.springer.com/article/10.1007/s40259-015-0132-7







Documentos relacionados